(University of Oklahoma) University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond. Using mass spectrometry, an analytical instrument for sensitive detection and accurate identification of molecules, the team will quantitate the amount of anti-cancer drugs present in individual cancer cells, including those in bladder cancer cells isolated from patients undergoing chemotherapy.
DiscussionRapidArc has an obvious advantage in improving the degree of target coverage, improving organs at risk, sparing healthy tissue, and significantly reducing the treatment time. FDG-PET/CT can increase the agreement between biopsies and delineated tumor volume and has the potential to positively impact the course of treatment. The Comet assay is attractive as a potential clinical test of tumor radiosensitivity. During radiotherapy, accurately defining disease areas is critical to avoid the unnecessary irradiation of normal tissue. Based on FDG-PET/CT and Comet assay, higher doses can be safely delivered to accurate …
To evaluate the accuracy of 11C-acetate Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) in bladder cancer (BC) staging and monitoring response to neoadjuvant chemotherapy (NAC).
ConclusionsNon-urothelial cancers of the urinary bladder are rare and mostly lack established protocols for treatment. The prognosis of most of these tumors is poor because they are usually advanced at the time of diagnosis. A multimodal treatment approach should be considered to improve outcomes.
The symptoms of stage 4 bladder cancer include tiredness, weakness, and pain. Stage 4 is the most advanced stage of cancer. The standard treatment for late-stage cancer is chemotherapy, but treatment will often focus on palliative care. Learn more about the symptoms of stage 4 bladder cancer and the survival rate here.
The treatment of non –muscle-invasive bladder cancer (NMIBC) remains a challenge because of its tendency to recur and progress [1,2]. To decrease the risk of recurrence, an immediate instillation of chemotherapy after transurethral resection (TURBT) is administered. The instillation prevents recurrence through eradica tion of floating tumor cells and residual tumor at the tumor site and by eradication of small overlooked synchronous tumors [3,4]. A recent systematic review and individual patient data meta-analysis by Sylvester et al.
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive t…
Our report and others suggest that certain patients with muscle invasive bladder cancer can avoid or defer radical cystectomy following a clinical complete response to neoadjuvant platinum based chemotherapy. Although we observed favorable outcomes in this highly select group of patients, there are several limitations and points of caution that must be acknowledged, as the comments highlight.
As surgeons our job is to intervene where the natural course of disease would lead to worsening illness, suffering and premature death, and observe patients who can be safely surveilled without intervention. Mazza et al present a retrospective series of 148 patients with muscle invasive bladder cancer who elected observation without radical cystectomy after a complete response to neoadjuvant chemotherapy. In a group of carefully selected patients from 2 high volume academic centers treated by 2 experienced surgeons the authors found overall 90% 5-year survival, which is on par with studies of patients who receive NAC with cystectomy.
BACKGROUND: In a recent meta-analysis, subgroups of patients were defined that may not benefit from a single, immediate instillation with chemotherapy. This led to a change in the European Association of Urology bladder cancer guidelines. In a previous paper, our group confirmed the efficacy of an immediate instillation of mitomycin C (MMC). However, prognostic groups in that study differ from those in the meta-analysis. Therefore, we performed a reanalysis using contemporary risk groups.
OBJECTIVES: To validate whether specific subgroups of patients with non-muscle-invasive bladder cancer (NMIBC) be…